Across 2,058 first-hand reports, people mentioned a side effect 175 times (about 9 per 100 reports). The most common: anhedonia, stomach issues, depression. User reports show what people notice — they can't tell you whether NAC is safe for you.
“I just had anhedonia from NAC. A few days of feeling depressed and anhedonic - glycine reversed it.”
“I tried so many things for depression like saffron rhodiola tyrosine omega 3 methylfolate B12 taurine theanine NAC inositol b complex magnesium nothing helps it.”
“Personally I find NAC intollerable, it gives me a dysfunctional kind of energy and terrible insomnia.”
“I recently started taking 2g of NAC/day and it's had an immediate and profound impact. Most notably I'm motivated again and have my energy back.”
“NAC has made me feel like a normal person again and has done what antidepressant meds could not.”
“And while my OCD is doing fine and I notice a drastic decrease of intrusive thoughts, I feel like shit due to agitation and irritability.”
Conclusion: Taken together, these preliminary findings suggest that dietetic approaches might be included as part of BD treatment. Also considering the high risk of metabolic disorders in individuals with BD, they should be encouraged to choose healthy dietary lifestyles, including daily intake of fruits, vegetables, seafood and whole grains.
Conclusion: Overall, NAC treatment appears to be safe and tolerable. Further well designed, larger controlled trials are needed for specific psychiatric and neurological disorders where the evidence is favorable.
Conclusion: These results highlight the paucity of randomised clinical trials comparing different interventions for paracetamol overdose and their routes of administration and the low or very low level quality of the evidence that is available. Evidence from a single trial found activated charcoal seemed the best choice to reduce absorption of paracetamol. Acetylcysteine should be given to people at risk of toxicity including people presenting with liver failure. Further randomised clinical trials with low risk of bias and adequate number of participants are required to determine which regimen results in